nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—ADRA1B—vas deferens—urinary bladder cancer	0.103	0.235	CbGeAlD
Loxapine—HTR7—vas deferens—urinary bladder cancer	0.06	0.137	CbGeAlD
Loxapine—CHRM3—ureter—urinary bladder cancer	0.0482	0.11	CbGeAlD
Loxapine—CHRM3—muscle of abdomen—urinary bladder cancer	0.0347	0.0792	CbGeAlD
Loxapine—HTR2A—urine—urinary bladder cancer	0.0093	0.0212	CbGeAlD
Loxapine—CHRM5—epithelium—urinary bladder cancer	0.00739	0.0169	CbGeAlD
Loxapine—CHRM2—prostate gland—urinary bladder cancer	0.00691	0.0157	CbGeAlD
Loxapine—ADRB1—prostate gland—urinary bladder cancer	0.00653	0.0149	CbGeAlD
Loxapine—CHRM1—prostate gland—urinary bladder cancer	0.00629	0.0143	CbGeAlD
Loxapine—ADRA1B—renal system—urinary bladder cancer	0.00627	0.0143	CbGeAlD
Loxapine—DRD5—female reproductive system—urinary bladder cancer	0.00612	0.014	CbGeAlD
Loxapine—CHRM3—prostate gland—urinary bladder cancer	0.00563	0.0128	CbGeAlD
Loxapine—ADRA1A—prostate gland—urinary bladder cancer	0.00517	0.0118	CbGeAlD
Loxapine—ADRA2C—prostate gland—urinary bladder cancer	0.00492	0.0112	CbGeAlD
Loxapine—ADRA2C—seminal vesicle—urinary bladder cancer	0.00416	0.00949	CbGeAlD
Loxapine—HRH1—prostate gland—urinary bladder cancer	0.004	0.00911	CbGeAlD
Loxapine—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00398	0.00908	CbGeAlD
Loxapine—HTR7—epithelium—urinary bladder cancer	0.00394	0.00897	CbGeAlD
Loxapine—ADRA2A—prostate gland—urinary bladder cancer	0.00393	0.00895	CbGeAlD
Loxapine—CHRM3—renal system—urinary bladder cancer	0.00383	0.00874	CbGeAlD
Loxapine—HTR1A—renal system—urinary bladder cancer	0.00382	0.00871	CbGeAlD
Loxapine—ADRA1A—epithelium—urinary bladder cancer	0.0038	0.00865	CbGeAlD
Loxapine—HTR7—smooth muscle tissue—urinary bladder cancer	0.00379	0.00864	CbGeAlD
Loxapine—HTR1B—female reproductive system—urinary bladder cancer	0.00379	0.00864	CbGeAlD
Loxapine—CHRM3—urethra—urinary bladder cancer	0.00377	0.00859	CbGeAlD
Loxapine—HTR1D—female reproductive system—urinary bladder cancer	0.00367	0.00836	CbGeAlD
Loxapine—HTR7—renal system—urinary bladder cancer	0.00365	0.00832	CbGeAlD
Loxapine—HTR2C—female reproductive system—urinary bladder cancer	0.00363	0.00828	CbGeAlD
Loxapine—ADRB1—female reproductive system—urinary bladder cancer	0.00357	0.00813	CbGeAlD
Loxapine—ADRA1A—renal system—urinary bladder cancer	0.00352	0.00803	CbGeAlD
Loxapine—SLC6A4—female reproductive system—urinary bladder cancer	0.00344	0.00785	CbGeAlD
Loxapine—CHRM1—female reproductive system—urinary bladder cancer	0.00343	0.00782	CbGeAlD
Loxapine—HRH2—lymph node—urinary bladder cancer	0.00336	0.00767	CbGeAlD
Loxapine—ADRA2C—renal system—urinary bladder cancer	0.00335	0.00765	CbGeAlD
Loxapine—ADRA2A—seminal vesicle—urinary bladder cancer	0.00332	0.00757	CbGeAlD
Loxapine—ADRA2C—urethra—urinary bladder cancer	0.0033	0.00751	CbGeAlD
Loxapine—CHRM3—female reproductive system—urinary bladder cancer	0.00307	0.007	CbGeAlD
Loxapine—SLC6A2—female reproductive system—urinary bladder cancer	0.00303	0.00691	CbGeAlD
Loxapine—HRH1—epithelium—urinary bladder cancer	0.00294	0.0067	CbGeAlD
Loxapine—HTR7—female reproductive system—urinary bladder cancer	0.00292	0.00666	CbGeAlD
Loxapine—HRH1—smooth muscle tissue—urinary bladder cancer	0.00283	0.00645	CbGeAlD
Loxapine—HRH1—urethra—urinary bladder cancer	0.00268	0.0061	CbGeAlD
Loxapine—ADRA2A—urethra—urinary bladder cancer	0.00263	0.00599	CbGeAlD
Loxapine—HTR2A—epithelium—urinary bladder cancer	0.00245	0.00559	CbGeAlD
Loxapine—ADRA2C—vagina—urinary bladder cancer	0.00243	0.00554	CbGeAlD
Loxapine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00236	0.00539	CbGeAlD
Loxapine—HTR2A—renal system—urinary bladder cancer	0.00228	0.00519	CbGeAlD
Loxapine—HRH1—female reproductive system—urinary bladder cancer	0.00218	0.00498	CbGeAlD
Loxapine—ADRA2A—female reproductive system—urinary bladder cancer	0.00214	0.00489	CbGeAlD
Loxapine—HRH1—vagina—urinary bladder cancer	0.00197	0.0045	CbGeAlD
Loxapine—ADRA2A—vagina—urinary bladder cancer	0.00194	0.00442	CbGeAlD
Loxapine—HTR2A—female reproductive system—urinary bladder cancer	0.00182	0.00416	CbGeAlD
Loxapine—SLC6A2—lymph node—urinary bladder cancer	0.00177	0.00404	CbGeAlD
Loxapine—HTR2A—vagina—urinary bladder cancer	0.00165	0.00376	CbGeAlD
Loxapine—ADRA2C—lymph node—urinary bladder cancer	0.00157	0.00358	CbGeAlD
Loxapine—Angiopathy—Etoposide—urinary bladder cancer	0.0015	0.00272	CcSEcCtD
Loxapine—Mediastinal disorder—Etoposide—urinary bladder cancer	0.00149	0.0027	CcSEcCtD
Loxapine—Leukopenia—Fluorouracil—urinary bladder cancer	0.00148	0.00269	CcSEcCtD
Loxapine—Vision blurred—Cisplatin—urinary bladder cancer	0.00148	0.00268	CcSEcCtD
Loxapine—Tremor—Cisplatin—urinary bladder cancer	0.00147	0.00266	CcSEcCtD
Loxapine—Cough—Gemcitabine—urinary bladder cancer	0.00147	0.00266	CcSEcCtD
Loxapine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00146	0.00266	CcSEcCtD
Loxapine—Alopecia—Etoposide—urinary bladder cancer	0.00146	0.00264	CcSEcCtD
Loxapine—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.00146	0.00264	CcSEcCtD
Loxapine—Hypertension—Gemcitabine—urinary bladder cancer	0.00145	0.00263	CcSEcCtD
Loxapine—Somnolence—Thiotepa—urinary bladder cancer	0.00145	0.00263	CcSEcCtD
Loxapine—Convulsion—Fluorouracil—urinary bladder cancer	0.00143	0.0026	CcSEcCtD
Loxapine—Chest pain—Gemcitabine—urinary bladder cancer	0.00143	0.0026	CcSEcCtD
Loxapine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00141	0.00256	CcSEcCtD
Loxapine—Photosensitivity—Doxorubicin—urinary bladder cancer	0.00141	0.00256	CcSEcCtD
Loxapine—Chest pain—Fluorouracil—urinary bladder cancer	0.00141	0.00255	CcSEcCtD
Loxapine—Fatigue—Thiotepa—urinary bladder cancer	0.00141	0.00255	CcSEcCtD
Loxapine—Dysgeusia—Etoposide—urinary bladder cancer	0.00141	0.00255	CcSEcCtD
Loxapine—Leukopenia—Cisplatin—urinary bladder cancer	0.0014	0.00255	CcSEcCtD
Loxapine—Constipation—Thiotepa—urinary bladder cancer	0.00139	0.00253	CcSEcCtD
Loxapine—Muscle spasms—Etoposide—urinary bladder cancer	0.00138	0.0025	CcSEcCtD
Loxapine—Oedema—Gemcitabine—urinary bladder cancer	0.00137	0.00249	CcSEcCtD
Loxapine—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.00136	0.00247	CcSEcCtD
Loxapine—Confusional state—Fluorouracil—urinary bladder cancer	0.00136	0.00247	CcSEcCtD
Loxapine—Convulsion—Cisplatin—urinary bladder cancer	0.00136	0.00246	CcSEcCtD
Loxapine—Oedema—Fluorouracil—urinary bladder cancer	0.00135	0.00245	CcSEcCtD
Loxapine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00135	0.00244	CcSEcCtD
Loxapine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00134	0.00244	CcSEcCtD
Loxapine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00134	0.00244	CcSEcCtD
Loxapine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00132	0.0024	CcSEcCtD
Loxapine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00132	0.0024	CcSEcCtD
Loxapine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00132	0.00239	CcSEcCtD
Loxapine—Leukopenia—Etoposide—urinary bladder cancer	0.00128	0.00233	CcSEcCtD
Loxapine—Hypotension—Gemcitabine—urinary bladder cancer	0.00128	0.00233	CcSEcCtD
Loxapine—Oedema—Cisplatin—urinary bladder cancer	0.00128	0.00232	CcSEcCtD
Loxapine—HRH1—lymph node—urinary bladder cancer	0.00128	0.00291	CbGeAlD
Loxapine—Loss of consciousness—Etoposide—urinary bladder cancer	0.00126	0.00229	CcSEcCtD
Loxapine—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.00126	0.00229	CcSEcCtD
Loxapine—Hypotension—Fluorouracil—urinary bladder cancer	0.00126	0.00229	CcSEcCtD
Loxapine—ADRA2A—lymph node—urinary bladder cancer	0.00125	0.00286	CbGeAlD
Loxapine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00125	0.00228	CcSEcCtD
Loxapine—Cough—Etoposide—urinary bladder cancer	0.00125	0.00227	CcSEcCtD
Loxapine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00125	0.00227	CcSEcCtD
Loxapine—Tachycardia—Cisplatin—urinary bladder cancer	0.00125	0.00227	CcSEcCtD
Loxapine—Convulsion—Etoposide—urinary bladder cancer	0.00124	0.00226	CcSEcCtD
Loxapine—Insomnia—Gemcitabine—urinary bladder cancer	0.00124	0.00225	CcSEcCtD
Loxapine—Hypertension—Etoposide—urinary bladder cancer	0.00124	0.00225	CcSEcCtD
Loxapine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00123	0.00224	CcSEcCtD
Loxapine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00122	0.00222	CcSEcCtD
Loxapine—Chest pain—Etoposide—urinary bladder cancer	0.00122	0.00222	CcSEcCtD
Loxapine—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00122	0.00221	CcSEcCtD
Loxapine—Insomnia—Fluorouracil—urinary bladder cancer	0.00122	0.00221	CcSEcCtD
Loxapine—Somnolence—Gemcitabine—urinary bladder cancer	0.00122	0.00221	CcSEcCtD
Loxapine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00121	0.0022	CcSEcCtD
Loxapine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.0012	0.00218	CcSEcCtD
Loxapine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.0012	0.00218	CcSEcCtD
Loxapine—Somnolence—Fluorouracil—urinary bladder cancer	0.0012	0.00218	CcSEcCtD
Loxapine—Hypotension—Cisplatin—urinary bladder cancer	0.00119	0.00217	CcSEcCtD
Loxapine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00118	0.00215	CcSEcCtD
Loxapine—Fatigue—Gemcitabine—urinary bladder cancer	0.00118	0.00215	CcSEcCtD
Loxapine—Confusional state—Etoposide—urinary bladder cancer	0.00118	0.00214	CcSEcCtD
Loxapine—Constipation—Gemcitabine—urinary bladder cancer	0.00117	0.00213	CcSEcCtD
Loxapine—Asthenia—Thiotepa—urinary bladder cancer	0.00117	0.00212	CcSEcCtD
Loxapine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00116	0.00211	CcSEcCtD
Loxapine—Dysphagia—Epirubicin—urinary bladder cancer	0.00115	0.0021	CcSEcCtD
Loxapine—Pruritus—Thiotepa—urinary bladder cancer	0.00115	0.00209	CcSEcCtD
Loxapine—Paraesthesia—Cisplatin—urinary bladder cancer	0.00115	0.00208	CcSEcCtD
Loxapine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00115	0.00208	CcSEcCtD
Loxapine—Tachycardia—Etoposide—urinary bladder cancer	0.00114	0.00208	CcSEcCtD
Loxapine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00114	0.00207	CcSEcCtD
Loxapine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00113	0.00205	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00113	0.00205	CcSEcCtD
Loxapine—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00113	0.00204	CcSEcCtD
Loxapine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00111	0.00202	CcSEcCtD
Loxapine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.0011	0.002	CcSEcCtD
Loxapine—Drowsiness—Methotrexate—urinary bladder cancer	0.0011	0.002	CcSEcCtD
Loxapine—Hypotension—Etoposide—urinary bladder cancer	0.00109	0.00199	CcSEcCtD
Loxapine—Renal failure—Methotrexate—urinary bladder cancer	0.00108	0.00196	CcSEcCtD
Loxapine—Dizziness—Thiotepa—urinary bladder cancer	0.00108	0.00196	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—urinary bladder cancer	0.00107	0.00194	CcSEcCtD
Loxapine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.00105	0.00191	CcSEcCtD
Loxapine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00105	0.00191	CcSEcCtD
Loxapine—Paraesthesia—Etoposide—urinary bladder cancer	0.00105	0.00191	CcSEcCtD
Loxapine—Weight increased—Epirubicin—urinary bladder cancer	0.00105	0.00191	CcSEcCtD
Loxapine—Weight decreased—Epirubicin—urinary bladder cancer	0.00104	0.0019	CcSEcCtD
Loxapine—Dyspnoea—Etoposide—urinary bladder cancer	0.00104	0.0019	CcSEcCtD
Loxapine—Somnolence—Etoposide—urinary bladder cancer	0.00104	0.00189	CcSEcCtD
Loxapine—Vomiting—Thiotepa—urinary bladder cancer	0.00104	0.00188	CcSEcCtD
Loxapine—Drowsiness—Epirubicin—urinary bladder cancer	0.00103	0.00187	CcSEcCtD
Loxapine—Rash—Thiotepa—urinary bladder cancer	0.00103	0.00187	CcSEcCtD
Loxapine—Dermatitis—Thiotepa—urinary bladder cancer	0.00103	0.00186	CcSEcCtD
Loxapine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.00103	0.00186	CcSEcCtD
Loxapine—Headache—Thiotepa—urinary bladder cancer	0.00102	0.00185	CcSEcCtD
Loxapine—Renal failure—Epirubicin—urinary bladder cancer	0.00101	0.00184	CcSEcCtD
Loxapine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00101	0.00184	CcSEcCtD
Loxapine—Fatigue—Etoposide—urinary bladder cancer	0.00101	0.00183	CcSEcCtD
Loxapine—Jaundice—Epirubicin—urinary bladder cancer	0.001	0.00182	CcSEcCtD
Loxapine—Constipation—Etoposide—urinary bladder cancer	0.001	0.00182	CcSEcCtD
Loxapine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000994	0.0018	CcSEcCtD
Loxapine—Hepatitis—Methotrexate—urinary bladder cancer	0.000988	0.00179	CcSEcCtD
Loxapine—Asthenia—Gemcitabine—urinary bladder cancer	0.000984	0.00179	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000975	0.00177	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—urinary bladder cancer	0.000972	0.00176	CcSEcCtD
Loxapine—Pruritus—Gemcitabine—urinary bladder cancer	0.000971	0.00176	CcSEcCtD
Loxapine—Nausea—Thiotepa—urinary bladder cancer	0.000969	0.00176	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—urinary bladder cancer	0.000967	0.00175	CcSEcCtD
Loxapine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000965	0.00175	CcSEcCtD
Loxapine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000961	0.00174	CcSEcCtD
Loxapine—Pruritus—Fluorouracil—urinary bladder cancer	0.000954	0.00173	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000953	0.00173	CcSEcCtD
Loxapine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000942	0.00171	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—urinary bladder cancer	0.000936	0.0017	CcSEcCtD
Loxapine—Jaundice—Doxorubicin—urinary bladder cancer	0.000929	0.00169	CcSEcCtD
Loxapine—Hepatitis—Epirubicin—urinary bladder cancer	0.000924	0.00168	CcSEcCtD
Loxapine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00092	0.00167	CcSEcCtD
Loxapine—Asthenia—Cisplatin—urinary bladder cancer	0.000917	0.00167	CcSEcCtD
Loxapine—Angiopathy—Methotrexate—urinary bladder cancer	0.000896	0.00163	CcSEcCtD
Loxapine—Dizziness—Fluorouracil—urinary bladder cancer	0.000892	0.00162	CcSEcCtD
Loxapine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00089	0.00162	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000889	0.00161	CcSEcCtD
Loxapine—Alopecia—Methotrexate—urinary bladder cancer	0.000873	0.00158	CcSEcCtD
Loxapine—Vomiting—Gemcitabine—urinary bladder cancer	0.000872	0.00158	CcSEcCtD
Loxapine—Rash—Gemcitabine—urinary bladder cancer	0.000865	0.00157	CcSEcCtD
Loxapine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000864	0.00157	CcSEcCtD
Loxapine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000863	0.00157	CcSEcCtD
Loxapine—Headache—Gemcitabine—urinary bladder cancer	0.000859	0.00156	CcSEcCtD
Loxapine—Vomiting—Fluorouracil—urinary bladder cancer	0.000858	0.00156	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000855	0.00155	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000851	0.00154	CcSEcCtD
Loxapine—Rash—Fluorouracil—urinary bladder cancer	0.00085	0.00154	CcSEcCtD
Loxapine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00085	0.00154	CcSEcCtD
Loxapine—Headache—Fluorouracil—urinary bladder cancer	0.000845	0.00153	CcSEcCtD
Loxapine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000842	0.00153	CcSEcCtD
Loxapine—Asthenia—Etoposide—urinary bladder cancer	0.00084	0.00153	CcSEcCtD
Loxapine—Angiopathy—Epirubicin—urinary bladder cancer	0.000839	0.00152	CcSEcCtD
Loxapine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000833	0.00151	CcSEcCtD
Loxapine—Pruritus—Etoposide—urinary bladder cancer	0.000829	0.0015	CcSEcCtD
Loxapine—Alopecia—Epirubicin—urinary bladder cancer	0.000817	0.00148	CcSEcCtD
Loxapine—Nausea—Gemcitabine—urinary bladder cancer	0.000815	0.00148	CcSEcCtD
Loxapine—Vomiting—Cisplatin—urinary bladder cancer	0.000813	0.00148	CcSEcCtD
Loxapine—Vision blurred—Methotrexate—urinary bladder cancer	0.00081	0.00147	CcSEcCtD
Loxapine—Rash—Cisplatin—urinary bladder cancer	0.000806	0.00146	CcSEcCtD
Loxapine—Dermatitis—Cisplatin—urinary bladder cancer	0.000805	0.00146	CcSEcCtD
Loxapine—Nausea—Fluorouracil—urinary bladder cancer	0.000801	0.00145	CcSEcCtD
Loxapine—Tension—Epirubicin—urinary bladder cancer	0.00079	0.00143	CcSEcCtD
Loxapine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000788	0.00143	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000776	0.00141	CcSEcCtD
Loxapine—Dizziness—Etoposide—urinary bladder cancer	0.000775	0.00141	CcSEcCtD
Loxapine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000774	0.0014	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000771	0.0014	CcSEcCtD
Loxapine—Leukopenia—Methotrexate—urinary bladder cancer	0.00077	0.0014	CcSEcCtD
Loxapine—Nausea—Cisplatin—urinary bladder cancer	0.00076	0.00138	CcSEcCtD
Loxapine—Vision blurred—Epirubicin—urinary bladder cancer	0.000758	0.00138	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—urinary bladder cancer	0.000756	0.00137	CcSEcCtD
Loxapine—Cough—Methotrexate—urinary bladder cancer	0.00075	0.00136	CcSEcCtD
Loxapine—Convulsion—Methotrexate—urinary bladder cancer	0.000745	0.00135	CcSEcCtD
Loxapine—Vomiting—Etoposide—urinary bladder cancer	0.000745	0.00135	CcSEcCtD
Loxapine—Agitation—Epirubicin—urinary bladder cancer	0.000739	0.00134	CcSEcCtD
Loxapine—Rash—Etoposide—urinary bladder cancer	0.000739	0.00134	CcSEcCtD
Loxapine—Dermatitis—Etoposide—urinary bladder cancer	0.000738	0.00134	CcSEcCtD
Loxapine—Headache—Etoposide—urinary bladder cancer	0.000734	0.00133	CcSEcCtD
Loxapine—Chest pain—Methotrexate—urinary bladder cancer	0.000732	0.00133	CcSEcCtD
Loxapine—Tension—Doxorubicin—urinary bladder cancer	0.000731	0.00133	CcSEcCtD
Loxapine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000729	0.00132	CcSEcCtD
Loxapine—Syncope—Epirubicin—urinary bladder cancer	0.000722	0.00131	CcSEcCtD
Loxapine—Leukopenia—Epirubicin—urinary bladder cancer	0.00072	0.00131	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000716	0.0013	CcSEcCtD
Loxapine—Confusional state—Methotrexate—urinary bladder cancer	0.000708	0.00128	CcSEcCtD
Loxapine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000707	0.00128	CcSEcCtD
Loxapine—Cough—Epirubicin—urinary bladder cancer	0.000702	0.00127	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000702	0.00127	CcSEcCtD
Loxapine—Convulsion—Epirubicin—urinary bladder cancer	0.000697	0.00127	CcSEcCtD
Loxapine—Nausea—Etoposide—urinary bladder cancer	0.000696	0.00126	CcSEcCtD
Loxapine—Hypertension—Epirubicin—urinary bladder cancer	0.000695	0.00126	CcSEcCtD
Loxapine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000688	0.00125	CcSEcCtD
Loxapine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000687	0.00125	CcSEcCtD
Loxapine—Chest pain—Epirubicin—urinary bladder cancer	0.000685	0.00124	CcSEcCtD
Loxapine—Agitation—Doxorubicin—urinary bladder cancer	0.000684	0.00124	CcSEcCtD
Loxapine—Dry mouth—Epirubicin—urinary bladder cancer	0.00067	0.00122	CcSEcCtD
Loxapine—Syncope—Doxorubicin—urinary bladder cancer	0.000668	0.00121	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000666	0.00121	CcSEcCtD
Loxapine—Confusional state—Epirubicin—urinary bladder cancer	0.000662	0.0012	CcSEcCtD
Loxapine—Oedema—Epirubicin—urinary bladder cancer	0.000657	0.00119	CcSEcCtD
Loxapine—Hypotension—Methotrexate—urinary bladder cancer	0.000656	0.00119	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000654	0.00119	CcSEcCtD
Loxapine—Cough—Doxorubicin—urinary bladder cancer	0.00065	0.00118	CcSEcCtD
Loxapine—Shock—Epirubicin—urinary bladder cancer	0.000646	0.00117	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—urinary bladder cancer	0.000645	0.00117	CcSEcCtD
Loxapine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000644	0.00117	CcSEcCtD
Loxapine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000643	0.00117	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—urinary bladder cancer	0.000643	0.00117	CcSEcCtD
Loxapine—Tachycardia—Epirubicin—urinary bladder cancer	0.000641	0.00116	CcSEcCtD
Loxapine—Insomnia—Methotrexate—urinary bladder cancer	0.000635	0.00115	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—urinary bladder cancer	0.000634	0.00115	CcSEcCtD
Loxapine—Paraesthesia—Methotrexate—urinary bladder cancer	0.00063	0.00114	CcSEcCtD
Loxapine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000626	0.00114	CcSEcCtD
Loxapine—Somnolence—Methotrexate—urinary bladder cancer	0.000624	0.00113	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—urinary bladder cancer	0.00062	0.00113	CcSEcCtD
Loxapine—Hypotension—Epirubicin—urinary bladder cancer	0.000614	0.00111	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—urinary bladder cancer	0.000613	0.00111	CcSEcCtD
Loxapine—Oedema—Doxorubicin—urinary bladder cancer	0.000608	0.0011	CcSEcCtD
Loxapine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000606	0.0011	CcSEcCtD
Loxapine—Fatigue—Methotrexate—urinary bladder cancer	0.000605	0.0011	CcSEcCtD
Loxapine—Shock—Doxorubicin—urinary bladder cancer	0.000598	0.00109	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000596	0.00108	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000595	0.00108	CcSEcCtD
Loxapine—Insomnia—Epirubicin—urinary bladder cancer	0.000594	0.00108	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000593	0.00108	CcSEcCtD
Loxapine—Paraesthesia—Epirubicin—urinary bladder cancer	0.00059	0.00107	CcSEcCtD
Loxapine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000585	0.00106	CcSEcCtD
Loxapine—Somnolence—Epirubicin—urinary bladder cancer	0.000584	0.00106	CcSEcCtD
Loxapine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000578	0.00105	CcSEcCtD
Loxapine—Hypotension—Doxorubicin—urinary bladder cancer	0.000568	0.00103	CcSEcCtD
Loxapine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000567	0.00103	CcSEcCtD
Loxapine—Fatigue—Epirubicin—urinary bladder cancer	0.000566	0.00103	CcSEcCtD
Loxapine—Constipation—Epirubicin—urinary bladder cancer	0.000562	0.00102	CcSEcCtD
Loxapine—Insomnia—Doxorubicin—urinary bladder cancer	0.00055	0.000997	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000546	0.00099	CcSEcCtD
Loxapine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000542	0.000983	CcSEcCtD
Loxapine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000541	0.000982	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—urinary bladder cancer	0.00054	0.00098	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000525	0.000952	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—urinary bladder cancer	0.000524	0.000951	CcSEcCtD
Loxapine—Constipation—Doxorubicin—urinary bladder cancer	0.00052	0.000943	CcSEcCtD
Loxapine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000517	0.000938	CcSEcCtD
Loxapine—Asthenia—Methotrexate—urinary bladder cancer	0.000503	0.000914	CcSEcCtD
Loxapine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000501	0.000909	CcSEcCtD
Loxapine—Pruritus—Methotrexate—urinary bladder cancer	0.000496	0.000901	CcSEcCtD
Loxapine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000484	0.000878	CcSEcCtD
Loxapine—Asthenia—Epirubicin—urinary bladder cancer	0.000471	0.000855	CcSEcCtD
Loxapine—Pruritus—Epirubicin—urinary bladder cancer	0.000465	0.000843	CcSEcCtD
Loxapine—Dizziness—Methotrexate—urinary bladder cancer	0.000464	0.000842	CcSEcCtD
Loxapine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000448	0.000813	CcSEcCtD
Loxapine—Vomiting—Methotrexate—urinary bladder cancer	0.000446	0.00081	CcSEcCtD
Loxapine—Rash—Methotrexate—urinary bladder cancer	0.000442	0.000803	CcSEcCtD
Loxapine—Dermatitis—Methotrexate—urinary bladder cancer	0.000442	0.000802	CcSEcCtD
Loxapine—Headache—Methotrexate—urinary bladder cancer	0.00044	0.000798	CcSEcCtD
Loxapine—Asthenia—Doxorubicin—urinary bladder cancer	0.000436	0.000791	CcSEcCtD
Loxapine—Dizziness—Epirubicin—urinary bladder cancer	0.000434	0.000788	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—urinary bladder cancer	0.00043	0.00078	CcSEcCtD
Loxapine—Vomiting—Epirubicin—urinary bladder cancer	0.000418	0.000758	CcSEcCtD
Loxapine—Nausea—Methotrexate—urinary bladder cancer	0.000417	0.000757	CcSEcCtD
Loxapine—Rash—Epirubicin—urinary bladder cancer	0.000414	0.000752	CcSEcCtD
Loxapine—Dermatitis—Epirubicin—urinary bladder cancer	0.000414	0.000751	CcSEcCtD
Loxapine—Headache—Epirubicin—urinary bladder cancer	0.000411	0.000747	CcSEcCtD
Loxapine—Dizziness—Doxorubicin—urinary bladder cancer	0.000402	0.000729	CcSEcCtD
Loxapine—Nausea—Epirubicin—urinary bladder cancer	0.00039	0.000708	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—urinary bladder cancer	0.000386	0.000701	CcSEcCtD
Loxapine—Rash—Doxorubicin—urinary bladder cancer	0.000383	0.000695	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000383	0.000695	CcSEcCtD
Loxapine—Headache—Doxorubicin—urinary bladder cancer	0.000381	0.000691	CcSEcCtD
Loxapine—Nausea—Doxorubicin—urinary bladder cancer	0.000361	0.000655	CcSEcCtD
Loxapine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	1.66e-06	0.00016	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	1.65e-06	0.00016	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	1.65e-06	0.000159	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	1.65e-06	0.000159	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	1.65e-06	0.000159	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—RHOA—urinary bladder cancer	1.65e-06	0.000159	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	1.64e-06	0.000158	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.64e-06	0.000158	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—SRC—urinary bladder cancer	1.64e-06	0.000158	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	1.63e-06	0.000158	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.63e-06	0.000157	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	1.63e-06	0.000157	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—MYC—urinary bladder cancer	1.63e-06	0.000157	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	1.63e-06	0.000157	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	1.63e-06	0.000157	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.62e-06	0.000156	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	1.62e-06	0.000156	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—SRC—urinary bladder cancer	1.61e-06	0.000156	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	1.61e-06	0.000155	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	1.61e-06	0.000155	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MYC—urinary bladder cancer	1.61e-06	0.000155	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	1.6e-06	0.000155	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	1.6e-06	0.000154	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	1.59e-06	0.000154	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	1.59e-06	0.000154	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.59e-06	0.000153	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	1.59e-06	0.000153	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	1.58e-06	0.000152	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.57e-06	0.000152	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	1.57e-06	0.000152	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	1.57e-06	0.000152	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	1.57e-06	0.000152	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	1.57e-06	0.000152	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—EGFR—urinary bladder cancer	1.57e-06	0.000152	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.56e-06	0.000151	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	1.56e-06	0.000151	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	1.56e-06	0.000151	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	1.56e-06	0.00015	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PTEN—urinary bladder cancer	1.55e-06	0.00015	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.55e-06	0.000149	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MYC—urinary bladder cancer	1.54e-06	0.000148	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.54e-06	0.000148	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	1.54e-06	0.000148	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.53e-06	0.000148	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	1.53e-06	0.000147	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.53e-06	0.000147	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	1.53e-06	0.000147	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	1.52e-06	0.000147	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	1.52e-06	0.000147	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.52e-06	0.000147	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.52e-06	0.000146	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	1.52e-06	0.000146	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.51e-06	0.000146	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	1.51e-06	0.000146	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	1.51e-06	0.000146	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.51e-06	0.000146	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	1.51e-06	0.000145	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—EGFR—urinary bladder cancer	1.5e-06	0.000145	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.5e-06	0.000145	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	1.5e-06	0.000145	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	1.5e-06	0.000145	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	1.5e-06	0.000144	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—KRAS—urinary bladder cancer	1.48e-06	0.000143	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—EP300—urinary bladder cancer	1.48e-06	0.000143	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1.48e-06	0.000143	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	1.48e-06	0.000142	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	1.47e-06	0.000142	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.47e-06	0.000142	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	1.47e-06	0.000142	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	1.47e-06	0.000142	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MYC—urinary bladder cancer	1.47e-06	0.000141	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.46e-06	0.000141	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	1.46e-06	0.000141	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.45e-06	0.00014	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	1.45e-06	0.00014	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.45e-06	0.00014	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.45e-06	0.00014	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.45e-06	0.00014	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	1.45e-06	0.000139	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MYC—urinary bladder cancer	1.45e-06	0.000139	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	1.44e-06	0.000139	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.44e-06	0.000139	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	1.44e-06	0.000139	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.44e-06	0.000139	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	1.44e-06	0.000139	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	1.44e-06	0.000138	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.43e-06	0.000138	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	1.43e-06	0.000138	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.43e-06	0.000138	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	1.43e-06	0.000137	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	1.42e-06	0.000137	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—KRAS—urinary bladder cancer	1.42e-06	0.000137	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.42e-06	0.000137	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	1.42e-06	0.000136	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	1.41e-06	0.000136	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	1.41e-06	0.000136	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	1.4e-06	0.000135	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	1.4e-06	0.000135	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TP53—urinary bladder cancer	1.4e-06	0.000135	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.4e-06	0.000135	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TP53—urinary bladder cancer	1.4e-06	0.000135	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	1.39e-06	0.000134	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	1.39e-06	0.000134	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	1.39e-06	0.000134	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	1.39e-06	0.000134	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	1.38e-06	0.000133	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	1.38e-06	0.000133	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	1.38e-06	0.000133	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	1.37e-06	0.000132	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	1.36e-06	0.000132	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	1.36e-06	0.000131	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—EP300—urinary bladder cancer	1.36e-06	0.000131	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	1.36e-06	0.000131	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	1.36e-06	0.000131	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	1.35e-06	0.000131	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.35e-06	0.000131	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	1.35e-06	0.00013	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	1.35e-06	0.00013	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	1.34e-06	0.000129	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	1.34e-06	0.000129	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	1.34e-06	0.000129	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—urinary bladder cancer	1.34e-06	0.000129	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	1.34e-06	0.000129	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	1.34e-06	0.000129	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.33e-06	0.000129	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	1.33e-06	0.000129	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	1.33e-06	0.000128	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	1.33e-06	0.000128	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	1.33e-06	0.000128	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.33e-06	0.000128	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—urinary bladder cancer	1.32e-06	0.000127	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	1.32e-06	0.000127	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	1.32e-06	0.000127	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.32e-06	0.000127	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	1.32e-06	0.000127	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.31e-06	0.000127	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	1.31e-06	0.000126	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.31e-06	0.000126	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	1.31e-06	0.000126	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	1.31e-06	0.000126	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	1.31e-06	0.000126	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.31e-06	0.000126	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	1.31e-06	0.000126	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	1.3e-06	0.000126	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.3e-06	0.000126	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	1.3e-06	0.000125	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	1.3e-06	0.000125	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	1.29e-06	0.000125	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	1.29e-06	0.000124	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.29e-06	0.000124	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	1.29e-06	0.000124	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	1.29e-06	0.000124	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.29e-06	0.000124	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	1.28e-06	0.000124	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	1.28e-06	0.000123	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	1.28e-06	0.000123	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	1.27e-06	0.000122	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	1.27e-06	0.000122	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—urinary bladder cancer	1.26e-06	0.000122	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—urinary bladder cancer	1.26e-06	0.000122	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	1.26e-06	0.000122	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	1.25e-06	0.000121	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	1.25e-06	0.000121	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	1.25e-06	0.00012	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	1.24e-06	0.00012	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	1.24e-06	0.000119	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	1.23e-06	0.000119	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	1.23e-06	0.000119	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	1.23e-06	0.000119	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	1.23e-06	0.000118	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	1.23e-06	0.000118	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	1.22e-06	0.000118	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	1.22e-06	0.000118	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	1.22e-06	0.000117	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	1.22e-06	0.000117	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	1.21e-06	0.000117	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	1.21e-06	0.000117	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—urinary bladder cancer	1.21e-06	0.000117	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	1.21e-06	0.000116	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	1.2e-06	0.000116	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—urinary bladder cancer	1.2e-06	0.000116	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	1.2e-06	0.000116	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	1.2e-06	0.000116	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.19e-06	0.000115	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	1.19e-06	0.000115	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	1.19e-06	0.000115	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	1.19e-06	0.000115	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	1.19e-06	0.000115	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—urinary bladder cancer	1.19e-06	0.000115	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	1.17e-06	0.000113	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	1.16e-06	0.000112	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	1.16e-06	0.000112	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	1.15e-06	0.000111	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	1.14e-06	0.00011	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	1.14e-06	0.00011	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	1.13e-06	0.000109	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	1.11e-06	0.000107	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	1.11e-06	0.000107	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	1.11e-06	0.000107	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	1.09e-06	0.000105	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	1.09e-06	0.000105	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	1.08e-06	0.000104	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	1.08e-06	0.000104	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	1.08e-06	0.000104	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	1.08e-06	0.000104	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	1.07e-06	0.000103	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	1.07e-06	0.000103	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	1.07e-06	0.000103	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	1.06e-06	0.000103	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	1.06e-06	0.000102	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	1.06e-06	0.000102	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	1.06e-06	0.000102	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	1.05e-06	0.000101	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	1.04e-06	0.000101	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	1.04e-06	9.98e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	1.03e-06	9.98e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	1.03e-06	9.93e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	1.03e-06	9.89e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	1.02e-06	9.86e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	1.01e-06	9.7e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	1e-06	9.68e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	1e-06	9.66e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	1e-06	9.65e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	9.97e-07	9.62e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	9.91e-07	9.55e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	9.9e-07	9.55e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	9.88e-07	9.53e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	9.86e-07	9.51e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	9.85e-07	9.5e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	9.85e-07	9.5e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	9.69e-07	9.34e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	9.58e-07	9.24e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	9.43e-07	9.09e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	9.15e-07	8.83e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	9.09e-07	8.76e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	8.94e-07	8.62e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	8.92e-07	8.61e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	8.89e-07	8.58e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	8.87e-07	8.55e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	8.78e-07	8.47e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	8.76e-07	8.44e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	8.69e-07	8.38e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	8.55e-07	8.25e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	8.53e-07	8.23e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	8.51e-07	8.2e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	8.48e-07	8.18e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	8.4e-07	8.1e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	8.37e-07	8.08e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	8.13e-07	7.85e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	7.78e-07	7.5e-05	CbGpPWpGaD
